Clinical Monograph: Oxycodone HCl 20 mg

Oxycodone HCl 20 mg modified-release packaging. Source: Taj Pharma India Ltd

1. Classification and Chemical Overview

Oxycodone is a semi-synthetic, pure opioid agonist derivative of the morphinan alkaloid thebaine. Chemically designated as (5$\alpha$)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride, it belongs to the phenanthrene class of opioids. Under the Anatomical Therapeutic Chemical (ATC) classification system, oxycodone is indexed under N02AA05.

Oxycodone HCl 20 mg is formulated as oral tablets or capsules containing 20 mg oxycodone hydrochloride (equivalent to 17.93 mg free oxycodone base). Internationally, oxycodone is classified as a controlled substance (e.g., Schedule II in the US; Class B / Schedule 2 Controlled Drug in the UK under the Misuse of Drugs Regulations) and is available strictly as a Prescription Only Medicine (POM). The 20 mg dose represents a higher-tier strength requiring careful dose titration or established opioid tolerance.

2. Mechanism of Action and Pharmacodynamics

Oxycodone exerts its primary analgesic and central physiological effects by acting as a full agonist at central and peripheral opioid receptors, demonstrating primary selectivity for $\mu$-opioid receptors alongside interactions at $\kappa$– and $\delta$-opioid receptors:

• $\mu$-Opioid Receptor Activation: Binds to G-protein-coupled $\mu$-receptors located on presynaptic and postsynaptic neuronal membranes throughout the central nervous system (brainstem, locus coeruleus, periaqueductal gray) and spinal cord (dorsal horn).

• Signal Transduction: Inhibits adenylyl cyclase activity, decreases intracellular cyclic AMP ($\text{cAMP}$), hyperpolarizes neuronal membranes by opening inwardly rectifying potassium channels, and inhibits voltage-gated calcium channels.

• Analgesic Transmission: Suppresses presynaptic release of nociceptive neurotransmitters (substance P, glutamate, CGRP), attenuating pain impulse conduction along spinothalamic pathways and altering central emotional perception of pain.

Additional systemic pharmacodynamic actions include dose-dependent respiratory center depression, sedation, miosis, cough suppression, gastrointestinal smooth muscle tone elevation (leading to delayed transit), and biliary sphincter spasm.

3. Approved Clinical Indications and Therapeutic Scope

Licensing for Oxycodone HCl 20 mg includes:

• Severe Pain Management: Treatment of severe acute or chronic pain that can only be adequately managed with potent opioid analgesics (e.g., severe postoperative pain, advanced cancer-related pain, and severe chronic non-cancer pain refractory to non-opioid step-down therapies).

Formulation Dynamics & Dosing Regimens:

• Immediate-Release (IR) 20 mg: Used primarily in opioid-tolerant patients or for rapid breakthrough pain titration. Administered every 4 to 6 hours as needed. In opioid-naïve individuals, an initial 20 mg IR dose carries a heightened risk of excessive sedation and respiratory depression; lower initial strengths (5 mg or 10 mg) are generally indicated for therapy initiation.

• Modified-Release / Prolonged-Release (MR) 20 mg: Formulated for continuous 12-hour drug delivery (e.g., OxyContin). Administered twice daily (every 12 hours) for stable, round-the-clock chronic pain control. Modified-release tablets must be swallowed whole and never crushed, chewed, or broken; disrupting the delivery matrix causes rapid drug release (“dose dumping”), leading to acute toxicity and potentially fatal overdose.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is high (60% to 87%) due to relatively low hepatic first-pass extraction. Peak plasma concentration (Cmax​) occurs within 1 to 2 hours (Tmax​) for immediate-release preparations and 3 to 5 hours for modified-release formulations.

• Distribution: Extensively distributed throughout body tissues following systemic uptake. Mean steady-state volume of distribution (Vd​) is approximately 2.6 L/kg. Plasma protein binding ranges between 38% and 45% (primarily to human serum albumin). Oxycodone crosses the blood-brain barrier and placenta, and is excreted in human breast milk.

• Biotransformation: Extensively metabolised in the liver via two main pathways:

  • CYP3A4 Pathway (Major): $N$-demethylation to noroxycodone, an inactive or weakly active circulating metabolite.

  • CYP2D6 Pathway (Minor): $O$-demethylation to oxymorphone, a potent opioid agonist present in lower systemic concentrations.

  • Metabolites undergo subsequent Phase II glucuronide conjugation.

• Elimination: Excreted predominantly via the kidneys in urine as conjugated metabolites and unchanged parent compound (< 10%). Elimination half-life (t1/2​) is approximately 3.2 to 5 hours for immediate-release formulations and 8 hours for modified-release formulations.

5. Physiological Effects and Adverse Event Spectrum

Oxycodone depresses central nervous system processing and slows peripheral gastrointestinal motility.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Constipation, nausea, vomiting, somnolence, dizziness, headache, pruritus.

• Common ($\ge 1/100$ to $<1/10$): Dry mouth, anorexia, abdominal pain, diarrhoea, dyspepsia, asthenia/fatigue, confusion, anxiety, depression, insomnia, hyperhidrosis, rash, bronchospasm.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Respiratory depression, profound sedation, miosis, biliary spasm, urinary retention, hallucination, agitation, euphoria, orthostatic hypotension, physical dependence/withdrawal symptoms, erectile dysfunction.

• Rare / Very Rare (<1/1,000): Anaphylactic reactions, paralytic ileus, seizures, opioid-induced hyperalgesia, adrenal insufficiency.

6. Contraindications, Drug Interactions, and Clinical Precautions

Kontraindikationen

• Known hypersensitivity to oxycodone or formulation excipients.

• Severe respiratory depression with hypoxia or hypercapnia.

• Severe chronic obstructive pulmonary disease (COPD) or acute severe bronchial asthma.

• Paralytic ileus or acute abdomen.

• Moderate to severe hepatic impairment (for modified-release formulations).

Key Drug Interactions

• CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin, Ritonavir, Grapefruit Juice): Inhibit oxycodone metabolic clearance, significantly elevating plasma drug levels and increasing the risk of fatal respiratory depression.

• CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, St. John’s Wort): Accelerate clearance, reducing therapeutic efficacy and potentially triggering withdrawal in dependent patients.

• CNS Depressants, Benzodiazepines, & Alcohol: Co-administration markedly increases the risk of profound sedation, life-threatening respiratory depression, coma, and fatal overdose.

• Monoamine Oxidase Inhibitors (MAOIs): Caution is required; co-administration may precipitate CNS excitation or severe depression.

Clinical Precautions and Monitoring

• Risk of Addiction, Misuse, and Abuse: Oxycodone 20 mg carries a substantial risk of opioid use disorder, dependence, and diversion. Prescribers should conduct comprehensive risk assessments prior to initiating therapy.

• Fatal Respiratory Depression: Life-threatening hypoventilation can occur even at therapeutic doses. Patients should be closely monitored, particularly during treatment initiation or following dose escalation to 20 mg.

• Tolerance & Tapering: Extended usage induces physical dependence. Abrupt discontinuation of a 20 mg daily regimen can trigger severe withdrawal symptoms (agitation, lacrimation, rhinorrhoea, diaphoresis, chills, myalgia, mydriasis). Dosage must be gradually tapered when discontinuing treatment.